Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISA 2020 | The evolution of AL amyloidosis therapy

Joel Buxbaum • 3 Sep 2020
ISA 2020
Amyloidosis Rare Diseases Antibodies Daratumumab Doxycycline Epigallocatechin-3-gallate Melphalan Prednisone TUDCA
ANDROMEDA

Many therapies for AL amyloidosis are derived from treatments commonly used for multiple myeloma, with initial trials investigating melphalan and prednisone. In this video Joel Buxbaum, MD, Scripps Research, La Jolla, CA, tells us about the evolution of AL amyloidosis therapy, delineating the trend of regimens that parallel that of multiple myeloma and commenting on alternative therapies such as TUDCA, doxycycline and epigallocatechin-3-gallate. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Joel Buxbaum

15:21
Genetic signatures & hereditary ATTR amyloidosis
Joel Buxbaum • 3 Sep 2020
5:43
Optimism for amyloidosis therapy
Joel Buxbaum • 3 Sep 2020

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals